AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22897785 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control) receiving no active treatment.
Number of subjects: 28
Study 22897785 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall long-term success rate of OIT.
Number of subjects: 28
Study 21898715 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 225
Study 21898715 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI (escitalopram)
Number of subjects: 225
Study 21898715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interpersonal psychotherapy and SSRI
Number of subjects: 225
Study 21898715 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 225
Study 19375019 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium plate
Number of subjects: 23
Study 19375019 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable plate
Number of subjects: 23
Study 16835599 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Trained (ET)
Number of subjects: 34
Study 16835599 — intervention group
Group type: COMPARATOR
Intervention: Moderately Trained (MT)
Number of subjects: 34
Study 16835599 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (SE)
Number of subjects: 34
Study 16835599 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (SE, MT, ET)
Number of subjects: 34
Study 14522732 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn Flakes (CF)
Number of subjects: 6
Study 14522732 — intervention group
Group type: COMPARATOR
Intervention: Bran Cereal (BC)
Number of subjects: 6
Study 10889153 — intervention group
Group type: COMPARATOR
Intervention: r-metHuBDNF (100 microg/kg SC daily for 2 weeks)
Number of subjects: 56
Study 10889153 — intervention group
Group type: COMPARATOR
Intervention: r-metHuNT-3 (300 microg/kg SC thrice weekly for 2 weeks)
Number of subjects: 56
Study 8742566 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14
Study 8742566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1560424 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed group (awareness of elevated blood pressure)
Number of subjects: 32
Study 1560424 — intervention group
Group type: COMPARATOR
Intervention: Control group (invited to coronary heart disease prevention program)
Number of subjects: 32
Study 3904336 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 11
Study 3904336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 11
Study 30118582 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen (1 g) + IV hydromorphone (0.5 mg)
Number of subjects: 81
Study 30118582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL normal saline) + IV hydromorphone (0.5 mg)
Number of subjects: 81
Study 29152847 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole + antidepressant therapy
Number of subjects: 0
Study 29152847 — intervention group
Group type: COMPARATOR
Intervention: placebo + antidepressant therapy
Number of subjects: 0
Study 26731172 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 54
Study 26731172 — intervention group
Group type: COMPARATOR
Intervention: Positive Psychotherapy (PPT)
Number of subjects: 54
Study 24709364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐Self(©) Plus Pain Control Program
Number of subjects: 0
Study 22362849 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine Determine(TM) TB-LAM point-of-care strip-test using microbiological reference standard with grade-1 cut-off point
Number of subjects: 423
Study 20032026 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental approach (insertion point 3 cm lateral to the midpoint of ischial tuberosity)
Number of subjects: 39
Study 20032026 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (prone subgluteal approach)
Number of subjects: 39
Study 17510577 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychosocial support by specially trained oncology nurses
Number of subjects: 179
Study 17510577 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychosocial support by psychologists
Number of subjects: 179
Study 17510577 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 179
Study 16103770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted protease inhibitor regimens (lopinavir, indinavir, saquinavir, amprenavir at 50%, 32%, 11%, and 6% respectively)
Number of subjects: 87
Study 16103770 — intervention group
Group type: EXPERIMENTAL
Intervention: NIQ (normalized inhibitory quotient) derived from Cmin/FC
Number of subjects: 87
Study 16103770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fold change (FC) and trough drug concentration (Cmin)
Number of subjects: 87
Study 11855668 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/day, p.o.) for 3 months
Number of subjects: 12
Study 11855668 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study 9720999 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) technique with bipolar surface electrodes
Number of subjects: 29
Study 9720999 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback on isometric force impulses
Number of subjects: 29
Study 8606538 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg once daily (n = 16)
Number of subjects: 36
Study 8606538 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg once daily (n = 20)
Number of subjects: 36
Study 2526717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate + EE (monophasic)
Number of subjects: 57
Study 2526717 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel + EE (monophasic)
Number of subjects: 57
Study 2526717 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene + EE (triphasic)
Number of subjects: 57
Study 2526717 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study 268331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol flavoured gum
Number of subjects: 24
Study 268331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose flavoured gum
Number of subjects: 24
Study 268331 — intervention group
Group type: COMPARATOR
Intervention: No oral hygiene and no chewing (control)
Number of subjects: 24
Study 268331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol flavoured gum (chewed 10 pieces for 3 hours)
Number of subjects: 24
Study 268331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose flavoured gum (chewed 10 pieces for 3 hours)
Number of subjects: 24
Study 30635021 — intervention group
Group type: EXPERIMENTAL
Intervention: Change score
Number of subjects: 0
Study 30635021 — intervention group
Group type: EXPERIMENTAL
Intervention: Post score
Number of subjects: 0
Study 29581519 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week online mindfulness intervention
Number of subjects: 67
Study 29581519 — intervention group
Group type: COMPARATOR
Intervention: internet-delivered psychoeducation
Number of subjects: 67
Study 27881518 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Habits for Life intervention (printed materials plus a personally tailored discussion)
Number of subjects: 0
Study 27881518 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 24731674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet or exercise or both)
Number of subjects: 577
Study 24731674 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 577
Study 22466022 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + attention training (EX + AMP)
Number of subjects: 112
Study 22466022 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest + attention training (REST + AMP)
Number of subjects: 112
Study 22466022 — intervention group
Group type: COMPARATOR
Intervention: Exercise + attention control condition (EX + ACC)
Number of subjects: 112
Study 22466022 — intervention group
Group type: COMPARATOR
Intervention: Rest + attention control condition (REST + ACC)
Number of subjects: 112
Study 18617572 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a friend
Number of subjects: 0
Study 18617572 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a peer
Number of subjects: 0
Study 17460332 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated sports drink (CES+CAF)
Number of subjects: 16
Study 17460332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17460332 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-electrolyte sports drink (CES)
Number of subjects: 16
Study 15249998 — intervention group
Group type: EXPERIMENTAL
Intervention: Birmingham Hip Resurfacing (BHR) for primary osteoarthritis
Number of subjects: 88
Study 15249998 — intervention group
Group type: COMPARATOR
Intervention: Birmingham Hip Resurfacing (BHR) for secondary osteoarthritis due to dysplasia
Number of subjects: 88
Study 15249998 — intervention group
Group type: EXPERIMENTAL
Intervention: Birmingham Hip Resurfacing (BHR) for both groups
Number of subjects: 88
Study 15249998 — intervention group
Group type: EXPERIMENTAL
Intervention: Birmingham Hip Resurfacing (BHR) for dysplastic hips
Number of subjects: 88
Study 11258648 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg b.i.d. (group A)
Number of subjects: 36
Study 11258648 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg b.i.d. (group B)
Number of subjects: 36
Study 11258648 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group C)
Number of subjects: 36
Study 10050994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cs-137 uterovaginal application followed by surgery (either immediate or delayed)
Number of subjects: 204
Study 8290186 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute regimen for labor induction
Number of subjects: 1801
Study 8290186 — intervention group
Group type: COMPARATOR
Intervention: 40-minute regimen for labor induction
Number of subjects: 1801
Study 8290186 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute regimen for labor augmentation
Number of subjects: 1801
Study 8290186 — intervention group
Group type: COMPARATOR
Intervention: 40-minute regimen for labor augmentation
Number of subjects: 1801
Study 3142593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 297
Study 3142593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 1494489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (18 IU per day)
Number of subjects: 12
Study 1494489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1494489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (3-fold higher dosage)
Number of subjects: 12
Study 152602 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscimol treatment
Number of subjects: 10
Study 31450958 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols available
Number of subjects: 365
Study 31450958 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis plans available
Number of subjects: 365
Study 31450958 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocols in 20% random sample
Number of subjects: 365
Study 31450958 — intervention group
Group type: EXPERIMENTAL
Intervention: A priori protocols in 20% random sample
Number of subjects: 365
Study 31450958 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis plans in 20% random sample
Number of subjects: 365
Study 31450958 — intervention group
Group type: EXPERIMENTAL
Intervention: A priori statistical analysis plans in 20% random sample
Number of subjects: 365
Study 30616657 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of ferric carboxymaltose (single dose)
Number of subjects: 48
Study 30616657 — intervention group
Group type: COMPARATOR
Intervention: 200 g/48 h of iron sucrose (fractionated doses)
Number of subjects: 48
Study 28239907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 1200 mg/day
Number of subjects: 103
Study 28239907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 26318714 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-bOPV-bOPV
Number of subjects: 570
Study 26318714 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-IPV-bOPV
Number of subjects: 570
Study 26318714 — intervention group
Group type: COMPARATOR
Intervention: IPV-IPV-IPV
Number of subjects: 570
Study 24210705 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and Reporting (MR)
Number of subjects: 253
Study 24210705 — intervention group
Group type: COMPARATOR
Intervention: Monitoring Alone (MA)
Number of subjects: 253
Study 23115399 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (4 hr in bed)
Number of subjects: 27
Study 23115399 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (9 hr in bed)
Number of subjects: 27
Study 19485842 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-guided treatment strategies
Number of subjects: 0
Study 19485842 — intervention group
Group type: COMPARATOR
Intervention: Conventional test-guided treatment strategies
Number of subjects: 0
Study 17691581 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at 80 Hz, 2.5 mA for 30 min, once every other day for 2 months
Number of subjects: 57
Study 17691581 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyl-chloroquine (6 mg/kg per day), oral transfer agent liquid, Vit B1, Vit B2, Vit C, fish-liver oil, and pilocarpine (20 mg/d) for 2 months
Number of subjects: 57
Study 15381891 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction intervention
Number of subjects: 0
Study 15381891 — intervention group
Group type: COMPARATOR
Intervention: Non-virtual reality distraction
Number of subjects: 0
Study 15381891 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual without distraction
Number of subjects: 0
Study 11433050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sn-mesoporphyrin (SnMP) administered as a single intramuscular dose of 6 micromol/kg birth weight within 24 +/- 12 hours of age
Number of subjects: 340
Study 11433050 — intervention group
Group type: COMPARATOR
Intervention: G‐6‐PD‐normal newborns (control group)
Number of subjects: 340
Study 11433050 — intervention group
Group type: COMPARATOR
Intervention: G‐6‐PD‐deficient newborns (comparison group)
Number of subjects: 340
Study 9851653 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 0
Study 9851653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7736844 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophagectomy without thoracotomy
Number of subjects: 96
Study 7736844 — intervention group
Group type: COMPARATOR
Intervention: Oesophagectomy via right thoracotomy and midline incision
Number of subjects: 96
Study 2591459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 10
Study 2591459 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 10
Study 5297557 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish BCG vaccine
Number of subjects: 3
Study 5297557 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish BCG vaccine
Number of subjects: 3
Study 5297557 — intervention group
Group type: EXPERIMENTAL
Intervention: Czechoslovak BCG vaccine
Number of subjects: 3
Study 31655974 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg every 4 weeks or 12 weeks)
Number of subjects: 3
Study 31655974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 30042075 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable emulsion
Number of subjects: 812
Study 30042075 — intervention group
Group type: COMPARATOR
Intervention: Unstable emulsion
Number of subjects: 812
Study 27021193 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 1276
Study 27021193 — intervention group
Group type: COMPARATOR
Intervention: CTC
Number of subjects: 1276
Study 24842175 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible tracheoscope
Number of subjects: 140
Study 24842175 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscope plus flexible tracheoscope
Number of subjects: 140
Study 24842175 — intervention group
Group type: COMPARATOR
Intervention: Control group (preformed stylet)
Number of subjects: 140
Study 22334228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Metformin 1000 mg/day (D+M)
Number of subjects: 27
Study 22334228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet, Metformin 500 mg/day and MYO 4 g/day plus 400 µg folic acid daily (D+M+I)
Number of subjects: 27
Study 22334228 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (D)
Number of subjects: 27
Study 21102966 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic medial branch blocks with bupivacaine (Group I)
Number of subjects: 100
Study 21102966 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic medial branch blocks with bupivacaine and non-particulate betamethasone (Group II)
Number of subjects: 100
Study 18569916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin applied once a week (n = 18)
Number of subjects: 36
Study 18569916 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin applied three times a week (n = 18)
Number of subjects: 36
Study 15750189 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg clopidogrel loading dose
Number of subjects: 255
Study 15750189 — intervention group
Group type: COMPARATOR
Intervention: 300-mg clopidogrel loading dose
Number of subjects: 255
Study 12356779 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein diet (approximately 90 mg of total isoflavones/day)
Number of subjects: 28
Study 12356779 — intervention group
Group type: COMPARATOR
Intervention: Isoflavone-deficient soy protein diet
Number of subjects: 28
Study 10856150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg twice daily (FP100BID)
Number of subjects: 570
Study 10856150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg once daily (FP200QD)
Number of subjects: 570
Study 10856150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 8857869 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured depression treatment program including behavioral treatment and counseling
Number of subjects: 153
Study 8857869 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured depression treatment program
Number of subjects: 153
Study 8857869 — intervention group
Group type: COMPARATOR
Intervention: Usual care by primary care physicians
Number of subjects: 153
Study 1535788 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate for 21 days combined with 250 micrograms levonorgestrel for the last ten days
Number of subjects: 29
Study 1535788 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate for 21 days combined with 10 mg medroxyprogesterone acetate for the last ten days
Number of subjects: 29
Study 6318543 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-521 20 mg once daily
Number of subjects: 10
Study 6318543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 10
Study 6318543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MK-521 and Hydrochlorothiazide
Number of subjects: 10
Study 6318543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31264767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 75 mg
Number of subjects: 140
Study 31264767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 140
Study 31264767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 140
Study 31264767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 30646261 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) plus practice facilitation (PF)
Number of subjects: 6699
Study 30646261 — intervention group
Group type: COMPARATOR
Intervention: Clinical decision support (CDS)
Number of subjects: 6699
Study 25926620 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 140 mg
Number of subjects: 1334
Study 25926620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1334
Study 25282309 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid attentional bias (AB)
Number of subjects: 47
Study 25282309 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid attentional bias for 200 ms cues
Number of subjects: 47
Study 25282309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-elicited craving
Number of subjects: 47
Study 25282309 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analyses controlling for pre-treatment opioid dependence diagnosis, opioid misuse, and pain severity
Number of subjects: 47
Study 22582760 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary cycling intervention for 3 months
Number of subjects: 62
Study 22582760 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 20433326 — intervention group
Group type: EXPERIMENTAL
Intervention: High Negative/Poorer Attention group
Number of subjects: 77
Study 18585976 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary drainage (PTBD)
Number of subjects: 54
Study 18585976 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic stenting (ES)
Number of subjects: 54
Study 15922197 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRCP (group 2)
Number of subjects: 63
Study 15922197 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC) and intraoperative cholangiography (IOC) (group 1)
Number of subjects: 63
Study 12234505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine (20 cc of 2% intrarectal lidocaine 20 minutes before biopsy)
Number of subjects: 100
Study 12234505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same amount of serum physiologic)
Number of subjects: 100
Study 12234505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine
Number of subjects: 100
Study 12234505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100